Changes in Hong Kong stocks | Hanson Pharmaceuticals (03692) rose more than 5% in the intraday HS-20093 osteosarcoma phase III clinical trial reached the main end point, and the company is preparing to apply for listing

The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose more than 5% in the intraday period. As of press release, it had risen 3.71% to HK$33.52, with a turnover of HK$372 million.

According to the news, Hanson Pharmaceuticals announced that the B7-H3 targeting antibody-drug conjugate (ADC) HS-20093, which was independently developed by the company, reached the main end point in a phase III clinical trial (ARTEMIS-011) to treat patients with osteosarcoma that progressed or recurred after receiving at least a second-line system treatment.

Progression-free survival (PFS) assessed by the independent review committee showed statistically significant and clinically significant improvements compared to the chemotherapy group; secondary endpoints such as overall survival (OS) and investigators' evaluation of PFS also showed consistent benefits; safety characteristics were consistent with previous studies, and no new safety signals were found. This achievement lays a key foundation for HS-20093 to submit a new drug marketing application in China. The company will soon begin communication with regulators and advance preparations for the marketing application; detailed data will be announced at future international oncology conferences.